An Open Label Study of IgG Fc Glycan Composition in Human Immunity

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

EARLY_PHASE1

Total Enrollment

129 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to produce better more effective vaccines, it is important to understand the particulars of why individuals have an effective or ineffective immune response to vaccination. We are going to examine specific aspects of the antibody (IgG Fc glycan) made by healthy volunteers who receive different vaccines or who have a viral infection to understand the nature of an effective (or less effective) vaccine response. The results of this research could be used to develop adjuvants to increase/ improve vaccine response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers

NCT01299662

Healthy Volunteers

COMPLETED PHASE1

Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects

NCT04408950

Immunodeficiency

COMPLETED

Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors

NCT03989050

Melanoma Non Small Cell Lung Cancer

WITHDRAWN

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

NCT04566692

Primary Immunodeficiency

COMPLETED PHASE4

Understanding COVID-19 Vaccine Immunity in Tissue and Blood

NCT05682625

COVID-19 (Coronavirus Disease 2019)

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Antibodies are principle mediators of immunity against infections and they can also give rise to autoimmune and inflammatory diseases. Two functional domains make up an IgG antibody - the Fab domain binds to a specific target, while the Fc domain can interact with receptor molecules to activate a pro- or anti- inflammatory state. The Fc domain of IgGs contains a glycan that is variable in composition and its specific sugar components are an important determinant of the biologic activity of IgGs in both protective and pathologic immune responses. New disease treatments could be developed through purposeful manipulation of IgG Fc glycans, but there is currently little known about how Fc glycan composition is regulated. We plan to study this by evaluating whether vaccination can cause changes in Fc glycan composition and, if so, whether signaling from helper T cells, age of the patient, and/or route of vaccine administration are determinants of specific modifications that are triggered by vaccination. Next, we will study effects that specific components within the Fc glycan have on immunity against the common human pathogens Streptococcus pneumoniae and influenza viruses using in vitro and in vivo models of infection. We will also study whether healthy adults who have been previously infected with dengue, zika or chikungunya virus generate distinct Fc glycoforms after vaccination compared with healthy adults who have not been previously infected with any of these viruses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Biologic/Vaccine, Age 18-64 cohort

Vaccination. IM Pneumococcal, meningococcal, or flu vaccine

Group Type ACTIVE_COMPARATOR

IM Pneumococcal, meningococcal, or flu vaccine

Intervention Type BIOLOGICAL

Volunteers given one of the 3 vaccines

Biologic/Vaccine, Age 65-80 cohort

Vaccination. IM Pneumococcal, meningococcal, or flu vaccine

Group Type ACTIVE_COMPARATOR

IM Pneumococcal, meningococcal, or flu vaccine

Intervention Type BIOLOGICAL

Volunteers given one of the 3 vaccines

Vaccine, healthy adults

Vaccination. IM Pneumococcal, meningococcal, or flu vaccine

Group Type ACTIVE_COMPARATOR

IM Pneumococcal, meningococcal, or flu vaccine

Intervention Type BIOLOGICAL

Volunteers given one of the 3 vaccines

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IM Pneumococcal, meningococcal, or flu vaccine

Volunteers given one of the 3 vaccines

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FluMist, Pneunomovax, or Menveo vaccine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or Female 18-80 years of age
* Healthy volunteers without significant medical problems
* Able to give informed consent to participate
* Willing to receive a single dose of an FDA-approved vaccine (either the influenza virus, pneumococcal or meningococcal vaccine)
* Documented previous infection with dengue, zika or chikungunya virus or no history of dengue, zika or chikungunya infection.

Exclusion Criteria

* Prior allergic reaction to commercial vaccination
* For Flumist participants: Close contact with person with severely compromised immune system requiring isolation
* For Flumist participants: Current illness that limits delivery to nasal airway (mild illness, such as diarrhea or mild respiratory infection with or without fever, and local infections do not apply)
* History of seizure disorder for Flumist group participants only.
* Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study.
* Any clinically significant acute or chronic medical condition requiring care of a physician (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that, in the opinion of the investigator, would preclude participation.
* In the opinion of the investigator, the volunteer is unlikely to comply with the study protocol.
* Currently taking systemic steroids or other immunomodulatory medications including anticancer medications and antiviral medications.
* Egg allergy
* Received the influenza vaccine less than 1 month ago and/or received the pneumococcal and meningococcal vaccine less than 4 years ago
* Confirmed HIV infection, positive for hepatitis B surface antigen or positive for hepatitis C antibodies.
* Is pregnant or lactating
* History of Guillain-Barre syndrome
* Poor venous access
* Unable to continue participation for 12 weeks
* Any clinically significant abnormality on medical history or physical examination including history of immunodeficiency or autoimmune disease.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes